Acton

Researchers are evaluating the effectiveness of the Erchonia40 FX-405 laser as a noninvasive additional treatment combined with standard periodontal scaling and root planing for improving the care of periodontal disease. This clinical study uses a double-blind design where neither the participants nor the investigators know who receives the active laser treatment or the placebo until the study concludes. All participants receive the standard care of scaling and root planing along with either the active or sham laser treatment. Participants will receive procedure administrations with either the Erchonia40 FX-405 laser or a placebo laser eight times over a five-month period. The treatment is divided into two phases: Phase One includes weekly treatments for four consecutive weeks, and Phase Two includes one treatment each month for the next four months. Each laser administration lasts 10 minutes and is done at the study site. Additionally, participants receive scaling and root planing before the first laser procedure and again at the three-month midpoint visit. During the study, participants will undergo clinical assessments including measuring changes in Clinical Attachment Loss at the primary tooth site from the start to eight months later. Researchers will monitor oral health and treatment effects with evaluations performed by blinded investigators. Participants must follow study-provided home care instructions and avoid other periodontitis treatments during the trial. The total participation time includes the five-month treatment phase and follow-up assessments to measure outcomes and safety.